Laura von Schantz, Vice President of Discovery at Alligator Bioscience, leads a discussion on the current and future opportunities of bispecific antibodies for solid tumour treatment.

Compared to non-solid tumours, solid tumours are more difficult to treat with conventional therapeutic methods. Antibody drug conjugates – biopharmaceutical drugs designed as a targeted therapy for treating cancer – represent a viable treatment alternative.

Nexelis Principal Scientist, Annett Kleinschmidt, explains the company’s efforts in measuring bactericidal antibody response.

Key opinion leaders from AbbVie, Ambrx Inc, and Antikor Biopharma talk about the cutting-edge technology’s promise for better therapeutic index.